LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "treatment hematological" as a keyword



Photo from archive.org

Artemisinin-type drugs for the treatment of hematological malignancies

Sign Up to like & get
recommendations! Published in 2020 at "Cancer Chemotherapy and Pharmacology"

DOI: 10.1007/s00280-020-04170-5

Abstract: Qinghaosu, known as artemisinin (ARS), has been for over two millennia, one of the most common herbs prescribed in traditional Chinese medicine (TCM). ARS was developed as an antimalarial drug and currently belongs to the… read more here.

Keywords: medicine; artemisinin type; hematological malignancies; type drugs ... See more keywords
Photo from archive.org

Antibody–Drug Conjugates for the Treatment of Hematological Malignancies: A Comprehensive Review

Sign Up to like & get
recommendations! Published in 2018 at "Targeted Oncology"

DOI: 10.1007/s11523-018-0558-1

Abstract: Antibody–drug conjugates (ADCs) are an emerging class of therapeutic agents that bring new opportunities for the treatment of hematological malignancies by meeting unmet medical needs. These drugs consist of a cytotoxic agent connected by a… read more here.

Keywords: hematological malignancies; antibody drug; drug conjugates; treatment hematological ... See more keywords
Photo from archive.org

Nanomedicines for the treatment of hematological malignancies

Sign Up to like & get
recommendations! Published in 2018 at "Journal of Controlled Release"

DOI: 10.1016/j.jconrel.2018.08.034

Abstract: Abstract Hematological malignancies (HM) are a collection of malignant transformations originating from cells in the primary or secondary lymphoid organs. Leukemia, lymphoma, and multiple myeloma comprise the three major types of HM. Current treatment consists… read more here.

Keywords: treatment; treatment hematological; hematological malignancies; nanomedicines treatment ... See more keywords
Photo from wikipedia

Humoral immunity to tetanus, diphtheria and polio in adults after treatment for hematological malignancies.

Sign Up to like & get
recommendations! Published in 2019 at "Vaccine"

DOI: 10.1016/j.vaccine.2019.11.034

Abstract: INTRODUCTION After chemotherapy, children with acute lymphocytic leukemia lose immunity and need revaccination against tetanus and diphtheria. However, little is known about immunity in adult patients after treatment for hematological malignancies. In this study, we… read more here.

Keywords: tetanus diphtheria; treatment; immunity; treatment hematological ... See more keywords
Photo by nci from unsplash

Pre-treatment hematological markers as a predictive biomarker for survival in patients with non-small cell lung cancer treated with nivolumab.

Sign Up to like & get
recommendations! Published in 2017 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2017.35.15_suppl.11547

Abstract: 11547Background: The absolute neutrophil count (ANC), absolute monocyte count (AMC) and neutrophil to lymphocyte ratio (NLR) are known markers of inflammation. We evaluated whether ANC, AMC and NLR... read more here.

Keywords: markers predictive; predictive biomarker; hematological markers; biomarker survival ... See more keywords